October 20, 2014
Fitch, Even, Tabin & Flannery LLP is pleased to announce that Jennifer R. Andrew has joined the firm’s Chicago office as an associate. A registered patent attorney, Jennifer focuses her practice on patent prosecution and preparation, IP licensing, and IP portfolio management. She has counseled clients ranging in size from startups to multinational corporations, working with technologies and industries that include food sciences, medical devices, and mechanical devices and processes.
Prior to joining Fitch Even, Jennifer was a patent attorney at the University of Illinois at Chicago. There she managed outside counsel regarding IP matters; negotiated, drafted, and reviewed license and other types of agreements; managed a large IP portfolio of early-stage biomedical, chemical, and mechanical technologies; drafted provisional patent applications; and reviewed and analyzed office actions, among other responsibilities.
Jennifer worked at a midsized IP law firm in Virginia at the start of her legal career, focusing primarily on serving clients in the mechanical and chemical arts. Before becoming a lawyer, Jennifer was a forensic DNA scientist with the Michigan State Police for nearly ten years. In that role she analyzed and interpreted DNA evidence, directed pre-trial conferences with attorneys and investigators, acted as a court-qualified expert, and trained scientists, prosecutors, and law enforcement professionals.
Jennifer earned her J.D., summa cum laude, from Michigan State University College of Law. She holds a B.S. in Microbiology from Michigan State University, where she also completed graduate-level coursework in Forensic Science.
We are happy to welcome Jennifer to the Fitch Even team!
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more